MDMA The New Way to Treat PTSD

How likely is the FDA to approve MDMA to treat PTSD? It is, after all, a psychedelic drug in Schedule I, which defines it as highly dangerous with no therapeutic value. Apparently, back in 2017, the FDA identified MDMA as a ‘breakthrough therapy’ for PTSD.

By |2021-02-25T20:10:08-08:00February 24, 2021|Articles & News, MDMA, Psychedelic Therapy, Studies|0 Comments

Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry in Jamaica

Aion Therapeutic Opening the First International Treatment Center for Psychedelic Psychiatry in Jamaica; Hires Leading Psychiatrist as Medical Director

Psychedelic Drug Therapy Now Offered at Calgary Clinic, The First Of Its Kind in Alberta

Currently, Health Canada grants exemptions that allow for individual therapy sessions using psilocybin for the terminally ill. The new clinic will start with this mandate, but Harder hopes to see it expand.

By |2021-02-20T02:08:31-08:00February 20, 2021|Articles & News, Magic Mushrooms|0 Comments

Could the Federal Government Help Legalize Psychedelics?

Psychedelics are going mainstream. Not only is the US FDA supportive of research, dozens of medical studies are proving such treatments could be helpful, including Johns Hopkins Medicine and New York University. In research to date, psilocybin has been found to help treat mental health issues, such as depression, anxiety, obsessive-compulsive disorder, and PTSD. LSD may be able to help patients with alcohol addiction and other mental disorders. MDMA-assisted therapy could help treat eating disorders, including anorexia and binge eating.

Major Potential For Cognitive Enhancer D-Lysergic Acid Diethylamide

sychedelic agonists of serotonin receptors induce neural plasticity and synaptogenesis, but their potential to enhance learning remains uncharted. Here we show that a single dose of d-LSD, a potent serotonergic agonist.

By |2019-12-08T05:24:53-08:00December 8, 2019|Articles & News, LSD|0 Comments

FDA States The Psychedelic Psilocybin is a ‘Breakthrough Therapy’ for Severe Depression

For the second time in a year, the U.S. Food and Drug Administration (FDA) has designated psilocybin therapy currently being tested in clinical trials as "breakthrough therapy," an action that is meant to accelerate the typically sluggish process of drug development and review.

By |2019-11-26T09:43:27-08:00November 26, 2019|Articles & News, Magic Mushrooms|0 Comments

Go to Top